We are delighted that our article ‘Stated preferences for relapsed or refractory mantle cell lymphoma treatments in Sweden and Germany’ has been published by Future Medicine. The article is based on work that Adelphi Research conducted with Janssen where we aimed to elicit treatment preferences in relapsed/refractory mantle cell lymphoma (r/r MCL).
What we did
The research involved a discrete-choice experiment comprising six attributes: ‘overall survival’, ‘progression-free survival’, ‘fatigue’, ‘nausea’, ‘risk of serious infections’ and ‘treatment administration’. The study included r/r MCL patients, physicians (haematologists and oncologists) treating r/r MCL patients and the general population in Sweden and Germany. In total 18 patients, 68 physicians and 191 members of the general population participated.
‘Overall survival’ was the most important attribute, followed by ‘risk of serious infection’ and ‘progression-free survival’ among physicians and the general population. In contrast, ‘treatment administration’ was the second most important attribute to patients, followed by ‘risk of serious infection’.
Preferences for characteristics differentiating treatments of r/r MCL varies between patients, physicians and members of the general population.